<DOC>
	<DOCNO>NCT03036150</DOCNO>
	<brief_summary>The purpose study evaluate effect dapagliflozin renal outcome cardiovascular mortality patient chronic kidney disease</brief_summary>
	<brief_title>A Study Evaluate Effect Dapagliflozin Renal Outcomes Cardiovascular Mortality Patients With Chronic Kidney Disease</brief_title>
	<detailed_description>This international , multicentre , event-driven , randomize , double-blind , parallel group , placebo-controlled study , evaluate effect dapagliflozin versus placebo , give daily addition standard care , prevent progression chronic kidney disease ( CKD ) cardiovascular ( CV ) /renal death</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Provision sign informed consent prior study specific procedure Female male age ≥18 year time consent eGFR ≥25 ≤75 mL/min/1.73m2 ( CKDEPI Formula ) UACR ≥200 ≤5000 mg/g visit 1 Stable , patient maximum tolerate labelled daily dose , treatment ACEI ARB least 4 week visit 1 , medically contraindicate , Autosomal dominant autosomal recessive polycystic kidney disease , lupus nephritis ANCAassociated vasculitis Receiving cytotoxic therapy , immunosuppressive therapy immunotherapy primary secondary renal disease within 6 month prior enrolment History organ transplantation Receiving therapy SGLT2 inhibitor within 8 week prior enrolment previous intolerance SGLT2 inhibitor Type 1 diabetes mellitus New York Heart Association ( NYHA ) class IV Congestive Heart Failure time enrolment MI , unstable angina , stroke transient ischemic attack within 12 week prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Kidney Disease ( CKD )</keyword>
	<keyword>Cardiovascular Events ( CV )</keyword>
	<keyword>Phase III outcome trial</keyword>
</DOC>